ESR1 and carcinoma: In fact, while it is reported that PR+ breast carcinomas are responsive to hormonal treatment, conversely, ER−/PR+ carcinomas tend to appear in premenopausal and younger patients (29–31) with a worse outcome if compared to younger ER+/PR+ patients (32).